Immunovant CFO Pamela Yanchik Connealy resigns effective July 16; transition consulting through Sept 9

Immunovant, Inc.

CFO Pamela Yanchik Connealy resigned effective July 16, 2021; no reason given.
She will provide transition consulting services through expected annual meeting (~Sept 9, 2021) at $375/hour.
Consulting agreement filed as Exhibit 10.1; she reports to CEO Peter Salzmann.
No immediate replacement for CFO named; transition period ends at annual meeting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Pamela Yanchik Connealy

Chief Financial Officer

IMVT · Immunovant, Inc.

Effective: 2021-07-16
Filed: July 13, 2021, 7:59 PM ET

On July 7, 2021, Pamela Yanchik Connealy, the Chief Financial Officer of Immunovant, Inc., resigned from Immunovant, such resignation to be effective on July 16, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Pamela Yanchik Connealy resigned as Chief Financial Officer at Immunovant, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On July 7, 2021, Pamela Yanchik Connealy, the Chief Financial Officer of Immunovant, Inc., resigned from Immunovant, such resignation to be effective on July 16, 2021.

View on SEC.gov

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-21-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.